GlobeImmune IPO: U.S. biopharmaceutical company GlobeImmune intends to go public on the Nasdaq Stock Exchange under the symbol “GBIM,” the proposed financing amount of $ 60 million. The company will offer its common shares at an IPO price range of $11-$13. On the basis of the assumed IPO price of $12, the median of the announced GlobeImmune IPO price range, GlobeImmune will command a market cap of $207 million. Wells Fargo Securities, and PiperJaffray are acting as the joint book-runners of GlobeImmune IPO.
GlobeImmune was founded in 1995, currently has four products currently in clinical trials. As of the 12 months ended June 30, 2012, the company recognized sales of $900.
Read the related article: GlobeImmune IPO application was submitted.